Parasite-Host Interaction and Pathophysiology Studies of the Human Relapsing Malarias Plasmodium vivax and Plasmodium ovale Infections in Non-Human Primates
Erica M. Pasini 
Clemens H. M. Kocken*- Department of Parasitology, Biomedical Primate Research Center, Rijswijk, Netherlands
Malaria remains a serious health concern across the globe. Historically neglected, non-Falciparum human malarias were put back on the agenda by a paradigm shift in the fight against malaria from malaria control to malaria eradication. Here, we review the modeling of the relapsing parasites Plasmodium vivax (P. vivax) and Plasmodium ovale (P. ovale) in non-human primates with a specific focus on the contribution of these models to our current understanding of the factors that govern parasite-host interactions in P. vivax and P. ovale parasite biology and pathophysiology.
Introduction
Malaria is a mosquito-transmitted disease that threatens 3.2 billion people in 95 countries (WHO, 2019 #2). The disease seriously impacts the poorest population living in the tropical and sub-tropical areas of the world. Furthermore, the socio-economic progress of developing countries (Gallup and Sachs, 2001) is hampered by the high mortality combined with an even higher burden of disease, known as morbidity. During the last decade a paradigm shift in the battle against malaria from malaria control to malaria eradication led to renewed attention for the historically neglected non-Falciparum malarias, which are known for their tendency to cause morbidity rather than high mortality (Thomson-Luque et al., 2019). Moreover, recent research has shown that the prospects of eradication may be threatened by an increase in the incidence of non-Falciparum human malarias, while the overall prevalence of Plasmodium falciparum, which is responsible for the high malaria mortality, is declining (Tanner et al., 2015). Here, we review the modeling of the relapsing parasites Plasmodium vivax (P. vivax) and Plasmodium ovale (P. ovale) in non-human primates with a specific focus on the contribution of these models to our current understanding of the factors that govern parasite-host interactions in P. vivax and P. ovale parasite biology and pathophysiology.
Human Plasmodium vivax and Plasmodium ovale Malaria
The relapsing human malaria parasites P. vivax and P. ovale are difficult to distinguish morphologically (Wenk and Stephens, 2000) and have both common and unique characteristics. The natural host of both parasites is man, both parasites are thought to form dormant liver stages [hypnozoites (Garnham et al., 1955; Coatney, 1976; Krotoski, 1985; Soulard et al., 2015)] that unpredictably reactivate in a strain-dependent manner (Battle et al., 2014; Veletzky et al., 2018) to produce relapses (Chin and Contacos, 1966; Chin and Coatney, 1971; Goljan et al., 2003; Centers for Disease and Prevention, 2005; Richter et al., 2010; Morgan et al., 2012; Groger et al., 2017) and form sexual transmissible stages called gametocytes from the very beginning of the sometimes still asymptomatic blood stage infection (Mckenzie et al., 2007; Mueller et al., 2009); both are characterized by a reticulocyte-restricted invasion phenotype (Kitchen, 1938; Rutledge et al., 2017; Thomson-Luque et al., 2019) and a clinical course that had originally been described as mild and benign (Kitchen, 1946; Kitchen, 1949; Collins and Jeffery, 2002; Collins and Jeffery, 2005) but can in fact be very severe (Maguire and Baird, 2010) including spontaneous spleen rupture (Facer and Rouse, 1991; Cinquetti et al., 2010; Zidouh et al., 2017), acute respiratory distress syndrome (Rojo-Marcos et al., 2008; Haydoura et al., 2011; Lacerda et al., 2012; Lau et al., 2013; Guerpillon et al., 2019) and lung injury (Lee and Maguire, 1999; Anstey et al., 2002; Anstey et al., 2007), acute pericarditis (Coton et al., 2011), myocardial infarction (Martin Polo et al., 2020), severe anemia (Erel et al., 1997; Hemmer et al., 2006; Douglas et al., 2012; Johnson et al., 2013; Graciaa et al., 2019), and cerebral malaria (Tanwar et al., 2011).
Due to their reticulocyte restricted phenotypes, in humans both parasites are characterized by relatively low parasitemia levels, rendering their study more complex. However, maximum parasitemia in P. ovale is considered to be generally lower than that observed in P. vivax malaria. It is widely accepted that both parasites occur globally (Sutherland et al., 2010; Oguike et al., 2011; Rutledge et al., 2017; Battle et al., 2019). However, prevalence differs due to the fact that most P. vivax strains are unable to invade Duffy negative red blood cells typical of the African population, while P. ovale is independent from the Duffy receptor (Welch et al., 1977). Furthermore, P. vivax is geographically the most widely distributed human malaria parasite, characterized by millions of clinical cases every year (WHO, 2016) and responsible for a massive economic burden (Gallup and Sachs, 2001), while large gaps still exist in our knowledge of the incidence and burden of disease for P. ovale malaria. Recent advances in sensitive PCR diagnosis show that low-level infections of this parasite seem to be common across malaria-endemic areas, often as complex mixed infections (Sutherland, 2016). However, our understanding of the interactions between P. ovale and other malaria parasites, which is essential for the deployment of suitable interventions (Dinko et al., 2013), is poor at best (Mueller et al., 2007; Maguire and Baird, 2010). Most recently two non-recombining sympatric forms of P. ovale were distinguished, P. ovale wallikeri and P. ovale curtisi (Sutherland et al., 2010; Fuehrer and Noedl, 2014). An observational study in British travelers showed that P. ovale wallikeri and P. ovale curtisi differ significantly in the duration of latency (Nolder et al., 2013). However, the role that the two P. ovale species are playing in the clinical presentation of “P. ovale” is still not fully defined; thus, hampering the understanding of the role of species differentiation for malaria treatment (Fuehrer and Noedl, 2014). A notable difference between the two forms was the absence of Schüffner’s stippling in P. ovale wallikeri blood forms. This finding may guide the differential diagnosis of the two P. ovale species (Phuong et al., 2016).
Human P. ovale and P. vivax infections have been modeled in non-human primates (NHP), either directly or using NHP surrogate parasites, in a number of NHP host species with alternate success as attempts were made to study their pathophysiological characteristics and understand their biology, to investigate co-infections and to establish robust vaccine and drugs testing avenues.
Modeling of Plasmodium vivax and Plasmodium ovale Human Malaria Infection in Chimpanzees (Pan troglodytes)
The important role of the spleen in parasite-host interactions was confirmed when the first infections with P. vivax and P. ovale were carried out in intact chimpanzees. While this model supported the development of the liver stages of both parasites, blood stage parasitemia was only transient (Rodhain, 1956; Bray, 1957a; Bray, 1957b; Morris et al., 1996). Upon splenectomy, however, high levels of P. vivax blood stage parasitemia were obtained (Young et al., 1975) (Krotoski et al., 1982b) and P. ovale parasitemia steadily increased for 10 days with a total duration of patent parasitemia of 21 days (Morris et al., 1996). Notably, the P. ovale blood infection in the chimpanzee differed from that in man by its tendency to produce blood schizonts with more than the usual number of merozoites (Collins et al., 1987a). While the role of the aberrant number of merozoites in unclear, it likely is the result of the parasite’s adaptation to its experimental hominidae host. It is unclear whether P. ovale related parasite species recently found in great apes (Duval et al., 2009; Mapua et al., 2018) also show this phenotype. Blood stage infections in splenectomized chimpanzees supported mosquito transmission (Young et al., 1975; Morris et al., 1996). However, in this context, parasite strain specific differences were found in the P. vivax-chimpanzee model between the Chesson strain and India VII strain. While infections with the former gave rise to variable blood parasitemia and thus, transmission was not always observed (Collins et al., 1986), infections with the latter generated reproducible, high mosquito transmission rates (Sullivan et al., 2001).
Overall, the chimpanzee model was used for two main purposes: 1) modeling host-parasite interactions in a host species closely related to the human host to study the tissue (liver) stages of the P. vivax (Bruce-Chwatt et al., 1970; Krotoski et al., 1982b; Nardin et al., 1982; Ferreira et al., 1986; Nardin, 1990) and P. ovale parasites (Bray et al., 1963) and 2) obtaining a stable, reproducible and high rate of mosquito transmission to establish a reliable source of parasites for monkey challenge studies and P. vivax vaccine development in New World Monkeys (Sullivan et al., 1996). As part of the first objective, numerous P. vivax strains, chiefly distinguishable by their biological characteristics, were studied in this model. When it comes to P. vivax strains, two main varieties have been defined: the so-called temperate (e.g., North Korean strain) and tropical strains (e.g., Madagascar strain). Differences in exoerythrocytic schizogony were determined in splenectomized chimpanzees through studies of prototypes strains of temperate and tropical strain varieties: compared to the Madagascar strain, which frequently relapsed, the North Korean strain showed a long latency period (Garnham et al., 1975). In the splenectomized chimpanzees, the patterns of these two strains were essentially indistinguishable from those observed in humans (Cogswell et al., 1983). In order to shed light on the different relapse behaviors of these two P. vivax parasite strains (Krotoski et al., 1986) a comparison between chimpanzee infections with the P. vivax Chesson and North Korean strains through the examination of hepatic biopsies obtained at day 7 and 10 post-infection was carried out. It revealed that in tissue obtained from animals infected with the Chesson strain both pre-erythrocytic schizonts and hypnozoites were present, while only rare hypnozoites at day 7 were observed in animals infected with the North Korean strain. As part of the P. vivax studies in chimpanzees it was also found that chimpanzee-passaged P. vivax could easily be re-transmitted back to humans (Garnham et al., 1956). The second objective, was considered important as the chimpanzee readily supported the development of infective gametocytes to a much greater extent than did Aotus or Saimiri monkeys (Collins et al., 1986). In 1990, the group of Mons managed to achieve the mass-scale production of P. vivax sporozoites in Anopheles stephensi using the chimpanzee as a source of infective blood (Ponnudurai et al., 1990).
Limited blood stage vaccine testing was also carried out in the P. vivax-chimpanzee model. The immunization with the merozoite surface protein-1(1–19) (MSP1–19) antigens of different Plasmodium species, including P. vivax, resulted in the detection of antibodies within 2 to 10 weeks post-immunization, which were broadly protective after P. vivax challenge in this model (Muerhoff et al., 2010). In another experiment aimed at understanding the efficacy of transmission blocking vaccines based on ookinete surface proteins Pvs25 and Pvs28, blood from chimpanzees infected with the P. vivax Salvador (Sal) I strain was mixed with antibodies against the yeast-produced ookinete surface recombinant proteins Pvs25 and Pvs28 and subsequently fed to mosquitoes. As a result, oocyst development in mosquitoes was completely blocked (Tsuboi et al., 2003). However, it is important to consider that chimpanzees are great apes and as such their use in scientific research has been banned, albeit with the exception of extreme scenarios that endanger human health or for the purpose of the preservation of hominidae species, by EU member states (EU, 2010; Altevogt et al., 2012), the UK (Office, 1998), New Zealand (Zealand, 1999), and Australia (Australian Government, 2003). Other states worldwide, such as Japan and the US, have restricted or are in the process of restricting the use of chimpanzees in scientific research (112th Congress, 2011; Kaiser, 2015).
Modeling of Plasmodium vivax and Plasmodium ovale Human Malaria Infection in New World Monkeys (Aotus, Saimiri, and Challitrix spp.)
New World monkeys are experimental, but not natural hosts of both P. vivax and P. ovale, which entails that both parasites need to be adapted to grow in these monkeys. The adaptation of P. ovale to grow in Saimiri monkeys was partially successful in that mature P. ovale liver stages were observed in this host, but no blood stages ensued (Millet et al., 1994b). However, Aotus monkeys were found to be refractory to P. ovale sporozoite infections (Coatney et al., 1971). Furthermore, both Aotus and Saimiri monkeys were completely refractory to infection with P. ovale infected red blood cells (Coatney et al., 1971; Millet et al., 1994b) from human or chimpanzee origin. This appears to show that host specificity for many malaria parasites occurs at the blood stage level (Millet et al., 1994b). This finding was further supported by studies with the P. vivax India VII strain in Aotus and Saimiri monkeys, which showed that the extended period before parasites appear in the blood stream depends on the difficulty with which exoerythrocytic derived merozoites adapt to heterologous erythrocytes (Sullivan et al., 2001). Ex vivo studies using non-human primate red blood cells and a murine anti-Fy6 monoclonal antibody allowed to uncover that the absence of the Fy6 on the Duffy receptor of macaque red blood cells, rendered them resistant to P. vivax but susceptible to the NHP malaria Plasmodium knowlesi. It was thus the presence of the Fy6 on the Duffy receptor of Aotus and Saimiri monkeys that made them a good host for P. vivax (Nichols et al., 1987; Barnwell et al., 1989). The P. vivax proteins binding to the Fy6 on the Duffy receptor were also identified using these models (Wertheimer and Barnwell, 1989). Single-cell gene expression profiles of 9,215 P. vivax parasites from bloodstream infections of Aotus and Saimiri monkeys provided new and robust markers of blood stage parasites, including some that are specific to the elusive P. vivax male gametocytes (Sa et al., 2020). While it has been proposed that long-term culture of P. vivax in the RBCs of Saimiri sciureus boliviensis may provide an alternative to the propagation of P. vivax in live animals the use of which is restricted and ethically complicated (Mehlotra et al., 2017), long-term culture of P. vivax in these conditions is cumbersome and Saimiri monkey RBCs are not widely available. The proteome from two biological replicates of infected S. s. boliviensis host reticulocytes undergoing the transition from late trophozoite to early schizont stages showed that a number of host and pathogen proteins contained highly oxidized or nitrated residues, supporting the possibility of oxidative stress in relation to the disease (Anderson et al., 2017). Ex vivo experiments using P. vivax infected Saimiri red blood cells were instrumental in providing evidence for the existence of the parasitophorous duct, establishing a continuity between the environment and the vacuolar space surrounding the intraerythrocytic parasite, which was first considered an in vitro artefact. These investigations showed stage and parasite species dependent variations of the characteristics of the duct’s structure (Pouvelle and Gysin, 1997). Using the P. vivax Achiote strain, Rossan and Baerg were one of the first to unequivocally demonstrate the presence and development of P. vivax exoerythrocytic stages in the liver of Saimiri monkeys (Rossan and Baerg, 1975). P. vivax model development in Aotus and Saimiri monkeys aimed at providing parasite-host combinations for chemotherapy, immunology, and biology studies, has provided an opportunity for learning about factors modulating parasite-host interactions and pathophysiology.
Characteristics of the P. vivax infections in New World Monkeys do not seem to depend on the donor species (human, chimpanzee or other Aotus/Saimiri monkey) of sporozoites or blood stage parasites, but appear to be modulated by intrinsic features of the P. vivax strain and the immuno-physiology of the recipient host. While the infection of S. s. boliviensis with chimpanzee-derived P. vivax Chesson strain sporozoites resulted in very long adaptation times (Collins et al., 1987b), the infection with chimpanzee-derived P. vivax Sal-I strain resulted in limited adaptation periods, high parasitemia levels, and good reproducibility of infection (Collins et al., 1988). In additional experiments, 67 splenectomized Aotus azarae boliviensis were infected with strains of P. vivax from Southeast Asia, New Guinea, North Korea, and Central America. Although all strains tested could be adapted to grow in this host, maximum parasitemia levels varied in a strain-dependent manner (VPA, ONG, Chesson, New Guinea, Sal-I > Salvador II > North Korean > Honduras I) and as expected, P. vivax strains that were subjected to more blood stage passages partially lost their ability to produce gametocytes and were thus less infective to mosquitoes (Collins et al., 1985c). In a similar experiment, Aotus vociferans (karyotype V, Peruvian owl monkey coming from Peru) was also found to be broadly susceptible to a variety of P. vivax strains. However, with peak parasite densities ranging from 4,840 to 75,500 per mm3, parasitemia levels in this Aotus species were generally lower than in Colombian and Bolivian Aotus species (Collins et al., 1987c).
Attempts to adapt a number of different strains show that there is an intrinsic difference in the susceptibility of different Aotus subspecies to the same P. vivax strain. Sporozoite infections with the P. vivax North Korean strain in splenectomized Aotus lemurinus griseimembra (Colombia; karyotypes: K-II, K-III, and K-IV) produced higher maximum parasitemia and more readily infected mosquitoes than did infections in A. a. boliviensis (Bolivia; karyotype: K-VI) or A. vociferans (Peru; K-V) and Aotus hershkovitzi (karyotype: K-X) (Collins et al., 1985b). While some level of immunity was expected to develop in the Aotus-P. vivax North Korean strain combinations, no immunity was observed during primary parasitemia, recrudescence, or relapse in this model (Collins et al., 1985b). Further supporting the notion that the host species plays a key role in modulating parasite adaption, infections with the P. vivax Panama strain were more successful in Aotus nancymaae (karyotype: K-I) than in other Aotus sub-species (Collins et al., 2002), while the P. vivax West Pakistan strain could only be established in A. l. griseimembra, in which only moderate parasitemia levels were observed (Collins et al., 1981). The A. vociferans was completely refractory to infections with sporozoites and only partially susceptible to infections with blood stages of the P. vivax ONG/CDC strain isolated from Vietnamese refugees (Collins et al., 1987c), while A. l. griseimembra and A. a. boliviensis were highly susceptible (Collins et al., 1983). Interestingly, while both P. vivax ONG/CDC and NAM/CDC (another strain isolated from Vietnamese refugees) infections in humans readily transmitted to a plethora of mosquitoes, a strongly differential mosquito tropism is observed as a result of Aotus infections (Collins et al., 1983). Both Vietnamese refugees’ strains are easily adapted to A. l. griseimembra and A. a. boliviensis where a long-lasting chronic parasitemia is observed making this host species-parasite combinations potential models for immunological studies into chronic human malaria infections. Splenectomized A. l. griseimembra was also suggested to considerably mimicking the course of Chesson malaria in humans in terms of parasitemia and mosquito infection (Collins et al., 2009). Similar differences in susceptibility between subspecies were observed also in Saimiri monkeys infected with P. vivax Sal-I where Bolivian phenotype Saimiri monkeys (S. s. boliviensis) appeared to develop higher peak parasitemia than Peruvian and Guyanan phenotypes (Campbell et al., 1983; Collins et al., 2008). Interestingly, a difference was observed in the S. s. boliviensis-P. vivax Sal-I model in the virulence of merozoites released by early developing exoerythrocytic schizonts ranging from those producing high-level parasitemia to those inducing low-density avirulent infections (Collins et al., 1996; Arevalo-Herrera and Herrera, 2001). Thus, factors specific to single S. s. boliviensis individuals appear to further modulate the virulence of P. vivax Sal-I infection in these monkeys. Moreover, a clear difference in susceptibility between Aotus and Saimiri monkeys to the P. vivax Sal-I strain was established, which led to questions related to the ability of P. vivax Sal-I to invade Saimiri monkeys’ reticulocytes. It was found that while P. vivax Sal-I uses the conventional Duffy binding protein (DBP-I/DBP-II)-mediated pathway to enter Aotus monkey red blood cells (McHenry et al., 2010). However, DBP-I is unable to bind to Saimiri monkey red blood cells. Thus, P. vivax Sal I must invade Saimiri monkey red blood cells independently of DBP-I/DBP-II. The comparison using RNA sequencing (RNAseq) data of late-stage infections when invasion ligands are expressed in Aotus and Saimiri monkey red blood cells, led to the identification of the tryptophan-rich antigen and merozoite surface protein 3 (MSP3) families that were more abundantly expressed in Saimiri monkey compared with Aotus monkey infections. These genes may encode potential ligands responsible for P. vivax infections of Duffy-negative Africans (Gunalan et al., 2019).
The inoculum size also appears to have an impact on the reproducibility and parasitemia levels in S. s. boliviensis infections. While 1,000 sporozoites gave an unreliable rate of infection and 100,000 sporozoites were coupled with an increased number of pathological manifestations due to a very high parasitemia level, the optimum for the Sal-I strain was found to be 10,000 sporozoites (Collins et al., 1988). However, the success in establishing infection also depends on the recipient host’s species/sub-species. A possible role for the skin in modulating the sporozoite infection of Aotus and Saimiri monkeys becomes apparent when comparing the susceptibility of different Saimiri species to mosquito bites and direct i.v. injection of sporozoites. While S. boliviensis and Guyanensis were found to be uniformly susceptible to both routes of infection, green and black headed S. peruviensis were not susceptible to mosquito bites infections, while being susceptible to direct i.v. sporozoite injections (Collins et al., 1994). Although sporozoite infections in Aotus and Saimiri spp. are known to be poorer producers of P. vivax gametocytes than chimpanzee infections (Collins et al., 1986), in New World monkeys the differential ability intrinsic to specific P. vivax strains to produce gametocytes appears to be further modulated by the host. While transmission of the P. vivax Thai strain could readily be achieved from infected chimpanzees, no transmission was obtained from either S. s. boliviensis, A. nancymaae, and A. l. griseimembra and only limited transmission was obtained after 3 linear passages from A. a. boliviensis in multiple attempts using different mosquito species (Anopheles freeborni, Anopheles stephensi, Anopheles dirus, Anopheles gambiae) (Collins et al., 1992). While both Saimiri and Aotus spp. infections with the Thai strain (polymorphic in CSP) resulted in blood stage parasitemia levels similar to other P. vivax strains, the reasons for the near-to complete absence of gametocytes from S. s. boliviensis, A. nancymaae, and A. l. griseimembra after limited passages is still a mystery (Collins et al., 1992). This is particularly surprising as in other Aotus species a direct relationship between parasitemia counts and mosquito infectivity was observed (Collins et al., 1985b). The Colombian Rio Meta strain, which was adapted to grow in Aotus for its unique transmission characteristics (transmissibility to the Central American vector, Anopheles albimanus) confirms that a P. vivax strain’s ability to produce gametocytes is in part modulated by the host’s subspecies as A. l. griseimembra repeatedly showed higher transmission than A. nancymaae (Collins et al., 2004). Furthermore, infections in A. a. boliviensis with P. vivax Sal-II, a strain known to give high mosquito transmission (Collins et al., 1998) from Aotus spp., repeatedly and inexplicably failed to infect a number of different mosquito species (Collins et al., 1985a). Importantly, relapses could not reproducibly be established in the New World monkey-P. vivax models.
Studies on the Pathophysiology of Plasmodium vivax in Aotus and Saimiri Monkeys
Aotus and Saimiri monkeys used in malaria vaccine trials were routinely monitored for parasitemia and general well-being through hematology and clinical chemistry. Detailed histological analyses were carried out at necropsy, which offered a better understanding of the pathophysiology of P. vivax malaria in these two NHP species. While a correlation between the lack of protection after malaria challenge and significant changes in hematologic values was found in these studies, the hematological changes observed could not completely be attributed to the increase in the parasite counts or parasite load (Galland et al., 1998). Studies of the organ distribution of developing trophozoite- and schizont-infected red blood cells in such animals showed that the primary site for the infection in both the Aotus and Saimiri monkey was the splenic vasculature. Secondary organ involvement differed between hosts although some overlap did occur (Fremount and Rossan, 1990).
As a result of in-depth histological analyses of P. vivax parasites in organs of infected Aotus and Saimiri monkeys a considerable portion of immature gametocytes was found in the parenchyma of the bone marrow, while blood stage schizonts were less present in this area of the bone marrow as well as in liver sinusoids. The bone marrow thus appears to be an important reservoir for gametocytes development and proliferation of P. vivax parasites (Obaldia et al., 2018).
Of late, the relationship between tissue parasite load and histopathology in a cohort of naive, mostly splenectomized Saimiri monkeys (S. s. boliviensis) infected i.v. with the P. vivax Brazil VII strain blood stage parasites was characterized by quantitative parasitological and histopathological analyses. Highest injury levels were found in the lung, liver, and kidney, where pathology was found to be similar to reports from human autopsies. Correlations were found between parasite loads and the intensity of histopathological changes in the lung and liver tissues. In contrast, hemozoin, an inflammatory parasite byproduct was associated with kidney damage, but not directly with parasite load. These findings suggest relevant similarities in the histopathology between P. vivax infections in Saimiri monkeys and severe P. vivax in humans. It was also found that sera from P. vivax-infected Saimiri monkeys was able to inhibit Fc receptor-mediated phagocytosis and to inhibit ingestion of IgG by normal monkey spleen macrophages. Generally, inhibition was correlated with higher parasitemia (Shear et al., 1987). In vitro data obtained using Saimiri brain endothelial cells have demonstrated that P. vivax-infected red blood cells were able to cytoadhere under static and flow conditions to cells expressing endothelial receptors known to mediate the cytoadhesion of P. falciparum. Although P. vivax-infected red blood cells’ cytoadhesion levels were found to be 10-fold lower than those observed for P. falciparum-infected erythrocytes, the strength of the interaction was similar. Specific antisera directed again P. vivax VIR proteins, inhibited the P. vivax-infected red blood cells—endothelial cell interaction, thus demonstrating that cytoadhesion of P. vivax-infected red blood cells in this model was in part mediated by VIR proteins (Carvalho et al., 2010). Recently, severe thrombocytopenia, which is also observed in human severe P. vivax malaria cases, was observed during routine antimalarial drug efficacy trials in Aotus monkeys infected with the P. vivax AMRU-1 strain. This strain has been considered particularly pathogenic to Aotus monkeys, and it was suggested that thrombocytopenia rather than anemia should be regarded as an early indicator of drug treatment failure with this strain (Obaldia, 2007). Although several histological, hematological and clinical chemistry changes in the P. vivax infected Saimiri and Aotus monkeys reflect changes observed in severe P. vivax malaria in humans (Peterson et al., 2019), it is important to keep in mind that these models are experimental and thus non-natural models. Moreover, while seminal data are available, more research (e.g., detailed histopathological studies should be performed) would be necessary to validate specific P. vivax-new world monkey combinations for use as robust models in the study of the pathophysiology of specific clinical manifestations of human P. vivax malaria.
Notably, Aotus monkeys have been used in a number of sequential and co-infection studies involving different human malaria parasites. Aotus exposed to P. falciparum malaria after exposure to P. vivax malaria had increased parasitemia and significantly higher levels of mosquito infectivity than naïve monkeys. While monkeys exposed to P. vivax malaria after exposure to P. falciparum malaria did not show higher parasitemia levels; significantly higher levels of mosquito infectivity were observed also in this case. In A. azarae boliviensis infected with P. vivax, which had previously been exposed to P. falciparum and Plasmodium malariae infection higher blood stage malaria was observed with the Vietnam Palo Alto, Chesson and North Korean strains compared to monkeys with no history of malaria (Collins et al., 1985a). Thus, the introduction of another malaria species into a malaria endemic area may result in higher levels of mosquito infection and more rapid establishment and distribution of that species (Collins et al., 1979).
Surrogate NHP Models of Plasmodium ovale and Plasmodium vivax Malaria
Over the years P. vivax could be adapted to grow in a number of NHP models ranging from the chimpanzee, which is now being phased out of scientific research due to ethical reasons, to the Aotus and Saimiri monkeys, some of which are endangered species and, as a model in general, marred by limited accessibility due to their ecology. Thus, more accessible models have also been established using surrogate parasites. Plasmodium cynomolgi in particular, which is considered the P. vivax sister parasite due to their high phylogenetic relatedness (Pasini et al., 2017), has been an excellent and widely used model for P. vivax. Plasmodium cynomolgi is a simian relapsing parasite, which is readily transmitted by a number of mosquito species (Coatney et al., 1971). Interestingly, while infections of P. cynomolgi in humans were considered purely experimental (Eyles et al., 1960), zoonotic occurrences of P. cynomolgi malaria transmission to man have recently been reported in South-East Asia (Ta et al., 2014; Imwong et al., 2019). Two natural infection models, the P. cynomolgi-Macaca fascicularis and the P. cynomolgi-Macaca mulatta were used in the study of this parasite’s biology and pathophysiology.
Plasmodium cynomolgi Berok strain infections with both blood and sporozoite gave rise to extremely low blood stage parasitemia in the M. fascicularis model (Collins et al., 1999). However, infections with the P. cynomolgi Berok strain in M. mulatta induced high-density parasite counts; furthermore, M. mulatta readily supported the development of gametocytes infectious to different anopheline mosquitoes routinely maintained in the laboratory (Collins et al., 1999). Of particular interest was the presence of a patterns of every-other-day infectivity of Anophelines which persisted often for many days (Coatney et al., 1971). Adding to the versatility of the Macaca mulatta-P. cynomolgi model, the Berok strain of P. cynomolgi can now successfully be maintained in long-term in vitro culture (Chua et al., 2019), where the parasite has been shown to indiscriminately invade monkeys red blood cells (Kosaisavee et al., 2017). Over time different strains were adapted to grow in this model such as the M (Mulligan) and B (Bastianellii), the Gombak and the Cambodian strains, and M. mulatta (rhesus monkey) became the most used of the NHP species for modeling P. cynomolgi infections. Sporozoite induced infections with the B strain were found to peak slightly sooner than those with the M strain. However, the main difference between the two isolates lies in the parasite levels after sporozoite and blood stage inoculation, which are consistently higher for the B strain compared to the M strain indicating that there is an intrinsic biological difference between these two strains (Coatney et al., 1971). Although this model has been used extensively for drug (Flannery et al., 2013; Campo et al., 2015) and vaccine development for P. vivax (Galinski and Barnwell, 2008), which is beyond the scope of this review, important studies on hypnozoite biology and pathological features have been performed.
Pathophysiology Studies
Experiments with P. cynomolgi in M. mulatta made it possible to establish the true relapsing nature of this simian parasite (Hawking et al., 1948; Shortt et al., 1948; Shortt and Garnham, 1948a; Shortt and Garnham, 1948b; Shortt and Garnham, 1948c; Shortt et al., 1954). In 1970, Sodeman published the first ultrastructure of the P. cynomolgi EE bodies showing no evidence of degenerative changes in the liver cell due to parasitism (Sodeman et al., 1970). Numerous studies were carried out to investigate the origin of relapses, including liver biopsies aimed at confirming the presence of persistent, uninucleate, dormant pre-erythrocytic P. cynomolgi stages (Krotoski et al., 1981; Krotoski et al., 1982a; Krotoski et al., 1982c; Bray et al., 1985) or at studying their characteristics (Sinden et al., 1990). As part of these studies, the theory of cyclical development was established (Schmidt, 1986). Infections with the P. cynomolgi B strain in this model have been used to study lipid infiltration in host tissues in early (exoerythrocytic) and late (chronic) stages of malaria infection. Histochemically, significant infiltration of neutral and total lipids in liver during the exoerythrocytic stage and in liver and kidney in the erythrocytic stage was demonstrated (Mehrotra and Dutta, 1994). Furthermore, the P. cynomolgi-Macaca mulatta combination has been instrumental to modeling recrudescence, a hallmark of P. vivax, thus once again demonstrating the strong similarity between the two sister parasites (Kocken et al., 2009). Unlike relapse, which is the consequence of the reactivation of dormant liver stages (hypnozoites), recrudescence occurs when parasite blood stages persist at a sub-patent level in drug-treated or untreated individuals followed by a new return to patency. The P. cynomolgi model allows for the differentiation between recrudescence and relapse: by treating the P. cynomolgi infected M. mulatta with drugs selectively targeting P. cynomolgi blood stages, such stages can be eliminated, while leaving liver hypnozoites intact. The complete elimination of all blood stages can then be monitored and confirmed by PCR analysis thus enable the differentiation between recrudescence-derived enduring sub-patent blood stage levels and new blood stages derived from the reactivation of liver hypnozoites (Joyner et al., 2015).
While in the past hypnozoite biology of P. vivax liver stages could not be studied in vitro, thanks to the evolution of a sophisticated P. cynomolgi ex-vivo liver stage system using primary hepatocytes of M. mulatta (Zeeman et al., 2013), it is now possible to study hypnozoite biology and screen drugs against them in vitro and only evaluate the most promising in the in vivo model. Most recently, the up-to now lacking proof of hypnozoite reactivation has been obtained in this model using a dual fluorescent P. cynomolgi reporter line (Voorberg-van der Wel et al., 2020). Plasmodium cynomolgi ex-vivo liver stage cultures in M. fascicularis primary hepatocytes have also been used to model hypnozoite reactivation/relapse (Dembele et al., 2014) and for the testing of drugs against the liver stages of relapsing malaria parasites [hypnozoiticidal drugs, (Dembele et al., 2011)].
Clustering analysis on microarrays used to examine gene expression in the P. cynomolgi model revealed that a large number of genes involved in RNA processing showed distinct down-regulation during the initial liver phase of infection (Ylostalo et al., 2005). Pathway modeling further showed clear patterns of flux redistribution within the purine pathway of P. cynomolgi during infection that are reflected in data from humans infected with P. falciparum (Tang et al., 2018). Recent transcriptomic studies provided a novel molecular framework to enhance the understanding of the hypnozoite biology showing that pathways involved in quiescence, energy metabolism, and maintenance of genome integrity remain the prevalent pathways active in mature hypnozoites (Bertschi et al., 2018). Hypnozoites express only 34% of Plasmodium physiological pathways, while 91% are expressed in replicating schizonts (Voorberg-van der Wel et al., 2017). The liver-specific protein 2 (LISP2) protein was identified and characterized as an early molecular marker of liver stage development, the expression of which is able to discriminate between dormant hypnozoites and early developing parasites. It was demonstrated that prophylactic drugs selectively kill all LISP2-positive parasites, while LISP2-negative hypnozoites are only sensitive to anti-relapse drug tafenoquine or primaquine (Gupta et al., 2019).
Most recently, an additional model to the M. mulatta-P. cynomolgi to study hypnozoite-induced relapsing infection has been proposed, namely the Japanese macaque (Macaca fuscata)-P. cynomolgi B strain (Kawai et al., 2020).
Immunological and Physiology Studies
A study in the P. cynomolgi model showed that natural killer cell activity profile initially markedly decreased in the earlier stages of infection, but later recovers (Saxena and Biswas, 1990; Sinden et al., 1990). The immune response to P. cynomolgi infection in M. mulatta seemed to be mediated by anti-parasite, pro-inflammatory responses during primary infection with a transition to protective type 2 responses after repeat infection (Praba-Egge et al., 2002). Plasmodium cynomolgi total parasite antigens soluble in culture medium, when injected in M. mulatta iv, induced the synthesis and secretion of serum colony-stimulating factors (Singh and Dutta, 1991). Macaca mulatta infections initiated by P. cynomolgi B strain sporozoites recapitulated pathology of human malaria, including anemia and thrombocytopenia, with inter-individual differences in disease severity (Joyner et al., 2016). Furthermore, P. cynomolgi relapse infections can be clinically silent in macaques and thus not cause clinical malaria due to rapid memory B cell responses that help to clear asexual-stage parasites but still carry gametocytes (Joyner et al., 2019). Studies in the P. cynomolgi model revealed high levels of reticulocytosis. However, it remains unclear if the parasite itself is able to stimulate this reticulocytosis via a parasite-induced factor meant to increase reticulocyte availability and satisfy the parasite’s tropism, or whether it is a physiological reaction of the host to the infection (Fonseca et al., 2018). Concealment of a non-circulating infected RBC sub-population from the peripheral circulation during P. cynomolgi infection of M. mulatta was also shown, which may be an important aspect of the host-pathogen relationship (Fonseca et al., 2017). Furthermore, using systems analysis to model the alterations in cell populations in the bone marrow during P. cynomolgi infection of M. mulatta led to the hypothesis that malarial anemia may be driven by monocyte-associated disruption of the GATA-1/GATA-2 in erythroid progenitors resulting in insufficient erythropoiesis during acute infection (Tang et al., 2017).
The P. cynomolgi infection model was extensively used to study pathophysiological modifications occurring in pregnancy-related malaria. After P. cynomolgi infection, the placenta in M. mulatta demonstrated altered physiology. The electron-microscopic observations showed slight complete focal necrosis of the placental tissue, besides alterations in total protein, phosphatases, and proteinases were detected. These changes in cellular constituents of placenta during malaria infection were found to be responsible for the malfunctioning of the placenta and in turn, abnormal fetus development (Saxena et al., 1993). The altered distribution of acid phosphatase and alkaline phosphatase and the resulting changes in hydrolytic enzyme activities in malaria infected early gestational placenta have a direct bearing on functional and morphological integrity of the placental tissue, thus being responsible for early gestational fetal death and abortions (Saxena and Murthy, 2005). Furthermore, alterations able to affect the cellular metabolism, especially steroidogenesis and detoxification process, which in turn would affect the normal development of the fetus as well as maintenance of gestation were found (Saxena and Murthy, 2007).
Effects of Interferons, Cytokines, and Steroids on the Biology and Pathophysiology of Plasmodium cynomolgi
Prophylactic treatment with recombinant human gamma interferon (rHuIFN 0.1 mg/kg/day) had no protective effect against trophozoite-induced infections, but a strong protective effect against experimental infections with P. cynomolgi B sporozoites in M. mulatta suggesting that the interferon effect was limited to the exoerythrocytic stage of parasitic development (Maheshwari et al., 1986) thus indicating an inhibition of liver schizogony. Reducing the rHuIFN-gamma treatment in this model to three administrations given close to the time of infection was sufficient to achieve complete protection. However, the protection obtained using rHuIFN-gamma treatment was not enduring and animals were susceptible to reinfection (Puri et al., 1988). IL-1 treatment was effective only when applied before sporozoite inoculation. IL-2 and TNF were effective in higher doses (Maheshwari, 1990). Prophylactic treatment with a single dose of a potent interferon inducer and immune enhancer, 18 h before intravenous inoculation of sporozoites of P. cynomolgi B in the M. mulatta, completely abolished the infectivity of sporozoites. The inhibitory effect of poly ICLC is dose dependent (Puri et al., 1996). Furthermore, one subcutaneous injection of recombinant human IL-12 2 days before challenge with P. cynomolgi sporozoites fully protected M. mulatta. In this model rIL-12 protects monkeys through IFN-gamma-dependent elimination of P. cynomolgi-infected hepatocytes (Hoffman et al., 1997).
The administration of cortisone in P. cynomolgi infected M. mulatta monkeys during the primary attack resulted in the marked increase in the peripheral blood infection, while cortisone administration during latent stage or chronic infection caused recrudescences of exceptional severity. Findings suggest that cortisone-induced responses closely compare to reactions to splenectomy. The upsurge in disease derived from cortisone administration appear to result from reduction in the number of macrophages, rather than an inhibition of phagocytic activity as such (Schmidt and Squires, 1951). However, the protracted multiplication of the P. cynomolgi M strain in splenectomized M. mulatta was often correlated with the appearance of parasites that were less virulent for monkeys with intact spleen than for splenectomized ones. The observed parasite attenuation probably reflects the selection of spontaneously arising mutant characterized by a limited capacity to avoid splenic clearance processes and unscathed or increased capacity to multiply in splenectomized monkeys (Schmidt et al., 1987).
Non-Natural Infection Models: Plasmodium cynomolgi in New World Monkeys (Aotus and Saimiri spp.)
Analogously to P. vivax, P. cynomolgi infection models were successfully established in New World monkeys using the P. cynomolgi Berok, Gombak, Smithsonian, Cambodian, and B strains (Collins et al., 1999; Collins et al., 2005b; Sullivan et al., 2006). In general, high density parasite counts, good levels of gametocytes and very efficient transmission were observed. Comparable to P. vivax infections in the Aotus and Saimiri models, studies of different P. cynomolgi strains in Aotus monkeys show that the characteristics of any specific host-parasite combination depend both on the P. cynomolgi strain and on the sub-species of the infected Aotus monkey. Furthermore, Saimiri monkeys were found to be less susceptible than Aotus in infections with both P. vivax and P. cynomolgi (Collins et al., 2005b; Sullivan et al., 2006).
Co-Infection Studies
Co-infections with P. cynomolgi and simian immunodeficiency virus (SIV) suggest that such co-infections enhance SIV-induced disease progression and impair the anti-Plasmodium immune response (Koehler et al., 2009). SIV infection aggravates malaria pathophysiology in Chinese M. mulatta. The animals coinfected with SIV and P. cynomolgi had suppressed total CD4+ T cells, central memory T cells, and naïve T cells, which may result from the imbalanced immune activation and faster CD4+ T cell turnover (Liu et al., 2019).
Co-infection have also been reported between P. cynomolgi and Babesia spp. In such co-infection there was a significant decrease in P. cynomolgi parasitemia, which correlated with increases in the levels of proinflammatory monocytes and with higher C-reactive protein serum levels. Ongoing infection with Babesia microti parasites leads to suppression of malaria infection (van Duivenvoorde et al., 2010).
Neglected NHP-Simian Relapsing Malaria Parasite Models
Plasmodium cynomolgi is the most widely used model for relapsing malaria, but some studies have also been performed with other NHP relapsing malarias.
The Plasmodium fieldi-M. mulatta model has been used historically, but also more recently, for a number of biological studies including as a model for relapsing malaria parasites P. ovale and P. vivax and the testing of the effects of new radical curative drugs (Martinelli and Culleton, 2018). Experimental infections in M. mulatta (Warren et al., 1964) and M. fascicularis (Warren and Wharton, 1963) were established. However, the parasite’s blood stage unique staining characteristics are modified in these models. In 1971, relapses in the P. fieldi-M. mulatta model were first observed and published (Collins and Contacos, 1971). With the exception of P. cynomolgi, P. fieldi exo-erythrocytic changes in the M. mulatta are probably the most extensively studied (Held et al., 1967; Coombs et al., 1968). Plasmodium fieldi infection in the M. mulatta give rise to the relatively low-level parasitemia in non-spelenectomized M. mulatta, which does not appear to endanger the life or well-being of the host (Collins et al., 1984). Higher parasitemias and a marked increase in mosquito infectivity (290) were observed upon splenectomy of M. mulatta. The reproducibility of transmission studies using sporozoites of Anopheles dirus and Anopheles Stephensi mosquitoes suggests that this would be a good model system for a number of studies requiring sporozoite-induced infections (Collins et al., 1973b). In addition, P. fieldi antigens display high levels of cross-reactivity to antibodies of other malarias, which makes them useful in sero-epidemiological studies (Salfelder and Mannweiler, 1981; Knobloch et al., 1982; Gebreel et al., 1985).
The name Plasmodium simiovale was chosen for this new parasite found in toque macaques (Dissanaike, 1965), its natural host, to underline that it should be considered the simian counterpart of the human malaria parasite P. ovale. Experimentally, M. mulatta is susceptible to infection either by sporozoite or blood stage P. simiovale parasites (Collins and Contacos, 1979); the parasitemia never reaches a high level, even after splenectomy. As shown by the early attempts to cultivate exoerythrocytic stages of P. simiovale ex-vivo (Millet et al., 1994a), the P. simiovale-M. mulatta model, similarly to the P. fieldi-M. mulatta model, is considered an interesting model to study the peculiarity of P. vivax malaria: the formation of dormant liver stages known as hypnozoites (Collins et al., 1972; Cogswell et al., 1991), which can reactivate at a later time point leading to relapses (Collins and Contacos, 1974). The P. simiovale model has also been proposed as a model to study immune evasion mechanisms (Prajapati and Singh, 2014).
Plasmodium simium models in New World monkeys are also interesting. Plasmodium simium infects both New World monkeys (Coatney et al., 1971) and humans (Brasil et al., 2017). It has been adapted to grow in both intact and splenectomized (higher parasitemia) Saimiri and Aotus monkeys (Collins et al., 1973a) and has been used as an experimental model of P. vivax malaria infections and for the testing of candidate vaccine against malaria (Collins et al., 2005a). Although it remains to be established whether P. simium is a genuinely relapsing malaria parasite, its close genetic (Camargos Costa et al., 2015; Lalremruata et al., 2015) and biological (Collins et al., 1969; Collins et al., 1974) relationship to P. vivax, which led some authors to refer to it as P. simium/P. vivax (Lim et al., 2005; Grigg and Snounou, 2017) suggests that these models may deserve additional studies.
Discussion
Across time, the availability of NHP models for human malaria parasite infections has driven forward our understanding of parasite biology and pathophysiology through the study of parasite-host interaction and the testing of drugs and vaccines. Different NHP models have emerged as suitable for the study of P. vivax, which vary in their accessibility: while the chimpanzee model is being phased out of scientific research due to ethical concern, accessibility to Aotus and Saimiri models is restricted to specific primate centers due to their ecology and the Convention on International Trade in Endangered Species of Wild Fauna and Flora status of some subspecies. In this context, the P. cynomolgi-M. mulatta model has emerged as particularly useful for the study of P. vivax biology and pathophysiology due to the high phylogenetic relatedness between both the P. cynomolgi parasite and P. vivax (sister parasite) and its M. mulatta host and humans. While this natural infection model has been used extensively for the study of hallmarks of P. vivax infections in humans such as recrudescence and relapse, relapses could not be reproducibly established in the P. vivax-New World monkey models. However, quantitative parasitological and histopathological analyses carried out in these models, have shown great similarity with the results of human autopsies. Thus, for the study of pathophysiology the P. cynomolgi model and the P. vivax-Aotus/Saimiri models may be complementary.
Overall, it is clear that our knowledge of the hypnozoite biology of the relapsing human malarias has enormously benefitted from the availability of the highly reliable P. cynomolgi model. However, while this model well represents P. vivax biology and pathophysiology, it is unclear in how far it is suitable for the study of P. ovale. As reviewed, a plethora of models are available to study P. vivax biology, pathophysiology and for the testing of treatments (vaccines and drugs) against P. vivax malaria, but it is clear that the absence of a good and readily available NHP model for P. ovale has severely hampered research into this parasite species. In fact, the complete P. ovale parasite cycle in the vertebrate host could only be recreated in the chimpanzee, thus severely reducing the avenues available to study the biology and the pathophysiology of this parasite even now that new prospects are created by the recent sequencing of the P. ovale genome (Rutledge et al., 2017). In the spirit of finding and validating a suitable NHP model for P. ovale and increasing the knowledge of the biology of relapsing malarias in general other NHP models, which have been so far neglected, should be reconsidered and studied more in detail such as the P. fieldi and P. simiovale-M. mulatta and the P. simium-Aotus/Saimiri models.
Author Contributions
EP conception and writing of the manuscript. CK discussion, review, and editing of the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by a collaborative grant from the Bill and Melinda Gates Foundation (Grant Numbers OPP1023583 and OPP1141292).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
112th Congress U. (2011). “US Great Ape Protection Act; Great Ape Protection and Cost Savings Act”, in: H.R.1513.
Altevogt B. M., Pankevich D. E., Pope A. M., Kahn J. P. (2012). Research agenda. Guiding limited use of chimpanzees in research. Science 335, 41–42. doi: 10.1126/science.1217521
Anderson D. C., Lapp S. A., Barnwell J. W., Galinski M. R. (2017). A large scale Plasmodium vivax- Saimiri boliviensis trophozoite-schizont transition proteome. PLoS One 12, e0182561. doi: 10.1371/journal.pone.0182561
Anstey N. M., Jacups S. P., Cain T., Pearson T., Ziesing P. J., Fisher D. A., et al. (2002). Pulmonary manifestations of uncomplicated falciparum and vivax malaria: cough, small airways obstruction, impaired gas transfer, and increased pulmonary phagocytic activity. J. Infect. Dis. 185, 1326–1334. doi: 10.1086/339885
Anstey N. M., Handojo T., Pain M. C., Kenangalem E., Tjitra E., Price R. N., et al. (2007). Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. J. Infect. Dis. 195, 589–596. doi: 10.1086/510756
Arevalo-Herrera M., Herrera S. (2001). Plasmodium vivax malaria vaccine development. Mol. Immunol. 38, 443–455. doi: 10.1016/S0161-5890(01)00080-3
Australian Government, N.H.a.M.R.C (2003). Policy on the Care and Use of Non-Human Primates for Scientific Purposes.
Barnwell J. W., Nichols M. E., Rubinstein P. (1989). In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivax. J. Exp. Med. 169, 1795–1802. doi: 10.1084/jem.169.5.1795
Battle K. E., Karhunen M. S., Bhatt S., Gething P. W., Howes R. E., Golding N., et al. (2014). Geographical variation in Plasmodium vivax relapse. Malar. J. 13, 144. doi: 10.1186/1475-2875-13-144
Battle K. E., Lucas T. C. D., Nguyen M., Howes R. E., Nandi A. K., Twohig K. A., et al. (2019). Mapping the global endemicity and clinical burden of Plasmodium vivax 2000-17: a spatial and temporal modelling study. Lancet 394, 332–343. doi: 10.1016/S0140-6736(19)31096-7
Bertschi N. L., Voorberg-Van Der Wel A., Zeeman A. M., Schuierer S., Nigsch F., Carbone W., et al. (2018). Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression intodormancy. Elife 7, e4108. doi:10.7554/eLife.41081
Brasil P., Zalis M. G., De Pina-Costa A., Siqueira A. M., Junior C. B., Silva S., et al. (2017). Outbreak of human malaria caused by Plasmodium simium in the Atlantic Forest in Rio de Janeiro: a molecular epidemiological investigation. Lancet Glob. Health 5, e1038–e1046. doi: 10.1016/S2214-109X(17)30333-9
Bray R. S., Burgess R. W., Baker J. R. (1963). Studies on malaria in chimpanzees. X. The presumed second generation of the tissue phase of Plasmodium ovale. Am. J. Trop. Med. Hyg. 12, 1–12. doi: 10.4269/ajtmh.1963.12.1
Bray R. S., Krotoski W. A., Cogswell F. B., Garnham P. C., Rodriguez M., Guy M. W., et al. (1985). Observations on early and late post-sporozoite tissue stages in primate malaria. III. Further attempts to find early forms and to correlate hypnozoites with growing exo-erythrocytic schizonts and parasitaemic relapses in Plasmodium cynomolgi bastianellii infections. Trans. R Soc. Trop. Med. Hyg. 79, 269–273. doi: 10.1016/0035-9203(85)90357-8
Bray R. S. (1957a). Studies on malaria in chimpanzees. II. Plasmodium vivax. Am. J. Trop. Med. Hyg. 6, 514–520. doi: 10.4269/ajtmh.1957.6.514
Bray R. S. (1957b). Studies on malaria in chimpanzees. IV. Plasmodium ovale. Am. J. Trop. Med. Hyg. 6, 638–645. doi: 10.4269/ajtmh.1957.6.638
Bruce-Chwatt L. J., Garnham P. C., Shute P. G., Draper C. C. (1970). Induced double infection with Plasmodium vivax and P. falciparum in a splenectomized chimpanzee. Trans. R Soc. Trop. Med. Hyg. 64, 2.
Camargos Costa D., Pereira De Assis G. M., De Souza Silva F. A., Araujo F. C., De Souza Junior J. C., Braga Hirano Z. M., et al. (2015). Plasmodium simium, a Plasmodium vivax-relatedmalaria parasite: genetic variability of Duffy binding protein II and the Duffy antigen/receptor forchemokines. PLoS One 10, e0131339. doi: 10.1371/journal.pone.0131339
Campbell C. C., Collins W. E., Chin W., Roberts J. M., Broderson J. R. (1983). Studies of the Sal I strain of Plasmodium vivax in the squirrel monkey (Saimiri sciureus). J. Parasitol. 69, 598–601. doi: 10.2307/3281376
Campo B., Vandal O., Wesche D. L., Burrows J. N. (2015). Killing the hypnozoite–drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog. Glob. Health 109, 107–122. doi: 10.1179/2047773215Y.0000000013
Carvalho B. O., Lopes S. C., Nogueira P. A., Orlandi P. P., Bargieri D. Y., Blanco Y. C., et al. (2010). On the cytoadhesion of Plasmodium vivax-infected erythrocytes. J. Infect. Dis. 202, 638–647. doi: 10.1086/654815
Centers for Disease, C., and Prevention (2005). Late relapse of Plasmodium ovale malaria–Philadelphia, Pennsylvania, November 2004. MMWR Morb. Mortal. Wkly. Rep. 54, 1231–1233.
Chin W., Coatney G. R. (1971). Relapse activity in sporozoite-induced infections with a West African strain of Plasmodium ovale. Am. J. Trop. Med. Hyg. 20, 825–827. doi: 10.4269/ajtmh.1971.20.825
Chin W., Contacos P. G. (1966). A recently isolated West African strain of plasmodium ovale. Am. J. Trop. Med. Hyg. 15, 1–2. doi: 10.4269/ajtmh.1966.15.1
Chua A. C. Y., Ong J. J. Y., Malleret B., Suwanarusk R., Kosaisavee V., Zeeman A. M., et al. (2019). Robust continuous in vitro culture of the Plasmodium cynomolgi erythrocytic stages. Nat. Commun. 10, 3635. doi: 10.1038/s41467-019-11332-4
Cinquetti G., Banal F., Rondel C., Plancade D., De Saint Roman C., Adriamanantena D., et al. (2010). Splenic infarction during Plasmodium ovale acute malaria: first case reported. Malar. J. 9, 288. doi: 10.1186/1475-2875-9-288
Coatney G. R., Collines W., Warren M., Contacos P. G. (1971). The primate malarias (Bethesda, Maryland: Library of Congress).
Cogswell F. B., Krotoski W. A., Hollingdale M. R., Gwadz R. W. (1983). Identification of hypnozoites and tissue schizonts of Plasmodium vivax and P. cynomolgi by the immunoperoxidase method. Am. J. Trop. Med. Hyg. 32, 1454–1455. doi: 10.4269/ajtmh.1983.32.1454
Cogswell F. B., Collins W. E., Krotoski W. A., Lowrie R. C. Jr. (1991). Hypnozoites of Plasmodium simiovale. Am. J. Trop. Med. Hyg. 45, 211–213. doi: 10.4269/ajtmh.1991.45.211
Collins W. E., Contacos P. G. (1971). Observations on the relapse activity of Plasmodium fieldi in the rhesus monkey. J. Parasitol. 57, 29–32. doi: 10.2307/3277748
Collins W. E., Contacos P. G. (1974). Observations on the relapse activity of Plasmodium simiovale in the rhesus monkey. J. Parasitol. 60, 343. doi: 10.2307/3278480
Collins W. E., Contacos P. G. (1979). Infection and transmission studies with Plasmodium simiovale in the Macaca mulatta monkey. J. Parasitol. 65, 609–612. doi: 10.2307/3280329
Collins W. E., Jeffery G. M. (2002). A retrospective examination of sporozoite-induced and trophozoite-induced infections with Plasmodium ovale: development of parasitologic and clinical immunity during primary infection. Am. J. Trop. Med. Hyg. 66, 492–502. doi: 10.4269/ajtmh.2002.66.492
Collins W. E., Jeffery G. M. (2005). Plasmodium ovale: parasite and disease. Clin. Microbiol. Rev. 18, 570–581. doi: 10.1128/CMR.18.3.570-581.2005
Collins W. E., Contacos P. G., Guinn E. G. (1969). Observations on the sporogonic cycle and transmission of Plasmodium simium Da Fonseca. J. Parasitol. 55, 814–816. doi: 10.2307/3277221
Collins W. E., Contacos P. G., Jumper J. R. (1972). Studies on the exoerythrocytic stages of simian malaria. VII. Plasmodium simiovale. J. Parasitol. 58, 135–141. doi: 10.2307/3278260
Collins W. E., Contacos P. G., Guinn E. G., Skinner J. C. (1973a). Plasmodium simium in the Aotus trivirgatus monkey. J. Parasitol. 59, 49–51. doi: 10.2307/3278570
Collins W. E., Skinner J. C., Contacos P. G., Guinn E. G., Richardson B. B. (1973b). The influence of splenectomy on infections of Plasmodium fieldi in Macaca mulatta monkeys. J. Parasitol. 59, 41–48. doi: 10.2307/3278569
Collins W. E., Contacos P. G., Jumper J. R. (1974). Studies on the exoerythrocytic stages of simian malaria. IX. Plasmodium simium. J. Parasitol. 60, 674–676. doi: 10.2307/3278737
Collins W. E., Warren M., Skinner J. C., Richardson B. B., Kearse T. S. (1979). Effect of sequential infection with Plasmodium vivax and P. falciparum in the Aotus trivirgatus monkey. J. Parasitol. 65, 605–608. doi: 10.2307/3280328
Collins W. E., Contacos P. G., Skinner J. C., Stanfill P. S., Richardson B. B. (1981). Susceptibility of Peruvian Aotus monkeys to infection with different species of Plasmodium. Am. J. Trop. Med. Hyg. 30, 26–30. doi: 10.4269/ajtmh.1981.30.26
Collins W. E., Warren M., Skinner J. C., Huong A. Y., Nguyen-Dinh P. (1983). Observations on the infectivity of two strains of Plasmodium vivax from Vietnamese refugees to Aotus monkeys and anopheline mosquitoes. J. Parasitol. 69, 689–695. doi: 10.2307/3281142
Collins W. E., Skinner J. C., Stanfill P. S., Sutton B. B., Huong A. Y. (1984). Infection and transmission studies with the N-3 strain of Plasmodium fieldi in the Macaca mulatta monkey. J. Parasitol. 70, 422–427. doi: 10.2307/3281575
Collins W. E., Skinner J. C., Broderson J. R., Mehaffey P. C., Sutton B. B. (1985a). Infection of Aotus azarae boliviensis monkeys with different strains of Plasmodium vivax. J. Parasitol. 71, 239–243. doi: 10.2307/3281909
Collins W. E., Skinner J. C., Krotoski W. A., Cogswell F. B., Gwadz R. W., Broderson J. R., et al. (1985b). Studies on the North Korean strain of Plasmodium vivax in Aotus monkeys and different anophelines. J. Parasitol. 71, 20–27. doi: 10.2307/3281972
Collins W. E., Skinner J. C., Mehaffey P. (1985c). Infection of Aotus azarae boliviensis monkeys with the RO strain of Plasmodium cynomolgi. J. Parasitol. 71, 848–849. doi: 10.2307/3281732
Collins W. E., Mcclure H. M., Swenson R. B., Mehaffey P. C., Skinner J. C. (1986). Infection of mosquitoes with Plasmodium vivax from chimpanzees using membrane feeding. Am. J. Trop. Med. Hyg. 35, 56–60. doi: 10.4269/ajtmh.1986.35.56
Collins W. E., Pappaioanou M., Mcclure H. M., Swenson R. B., Strobert E., Skinner J. C., et al. (1987a). Infection of chimpanzees with Nigerian I/CDC strain of Plasmodium ovale. Am. J. Trop. Med. Hyg. 37, 455–459. doi: 10.4269/ajtmh.1987.37.455
Collins W. E., Skinner J. C., Pappaioanou M., Broderson J. R., Mcclure H. M., Strobert E., et al. (1987b). Chesson strain Plasmodium vivax in Saimiri sciureus boliviensis monkeys. J. Parasitol. 73, 929–934. doi: 10.2307/3282513
Collins W. E., Skinner J. C., Pappaioanou M., Ma N. S., Broderson J. R., Sutton B. B., et al. (1987c). Infection of Aotus vociferans (karyotype V) monkeys with different strains of Plasmodium vivax. J. Parasitol. 73, 536–540. doi: 10.2307/3282132
Collins W. E., Skinner J. C., Pappaioanou M., Broderson J. R., Filipski V. K., Mcclure H. M., et al. (1988). Sporozoite-induced infections of the Salvador I strain of Plasmodium vivax in Saimiri sciureus boliviensis monkeys. J. Parasitol. 74, 582–585. doi: 10.2307/3282173
Collins W. E., Sattabongkot J., Wirtz R. A., Skinner J. C., Broderson J. R., Millet P. G., et al. (1992). Development of a polymorphic strain of Plasmodium vivax in monkeys. J. Parasitol. 78, 485–491. doi: 10.2307/3283649
Collins W. E., Morris C. L., Richardson B. B., Sullivan J. S., Galland G. G. (1994). Further studies on the sporozoite transmission of the Salvador I strain of Plasmodium vivax. J. Parasitol. 80, 512–517. doi: 10.2307/3283184
Collins W. E., Sullivan J. S., Morris C. L., Galland G. G., Richardson B. B. (1996). Observations on the biological nature of Plasmodium vivax sporozoites. J. Parasitol. 82, 216–219. doi: 10.2307/3284148
Collins W. E., Richardson B. B., Morris C. L., Sullivan J. S., Galland G. G. (1998). Salvador II strain of Plasmodium vivax in Aotus monkeys and mosquitoes for transmission-blocking vaccine trials. Am. J. Trop. Med. Hyg. 59, 29–34. doi: 10.4269/ajtmh.1998.59.29
Collins W. E., Warren M., Galland G. G. (1999). Studies on infections with the Berok strain of Plasmodium cynomolgi in monkeys and mosquitoes. J. Parasitol. 85, 268–272. doi: 10.2307/3285631
Collins W. E., Sullivan J. S., Galland G. G., Williams A., Nace D., Williams T. (2002). Potential of the Panama strain of Plasmodium vivax for the testing of malarial vaccines in Aotus nancymai monkeys. Am. J. Trop. Med. Hyg. 67, 454–458. doi: 10.4269/ajtmh.2002.67.454
Collins W. E., Sullivan J. S., Galland G. G., Barnwell J. W., Nace D., Williams A., et al. (2004). Rio Meta strain of Plasmodium vivax in NewWorld monkeys and anopheline mosquitoes. J. Parasitol. 90, 685–688. doi: 10.1645/GE-3361
Collins W. E., Sullivan J. S., Galland G. G., Williams A., Nace D., Williams T., et al. (2005a). Plasmodium simium and Saimiri boliviensis as a model system for testing candidate vaccines against Plasmodium vivax. Am. J. Trop. Med. Hyg. 73, 644–648.
Collins W. E., Warren M., Sullivan J. S., Galland G. G., Nace D., Williams A., et al. (2005b). Studies on two strains of Plasmodium cynomolgiin New World and Old World monkeys and mosquitoes. J. Parasitol. 91, 280–283. doi: 10.1645/GE-3418
Collins W. E., Sullivan J. S., Nace D., Williams T., Williams A., Barnwell J. W. (2008). Observations on the sporozoite transmission ofPlasmodium vivax to monkeys. J. Parasitol. 94,287–288. doi: 10.1645/GE-1283.1
Collins W. E., Sullivan J. S., Strobert E., Galland G. G., Williams A., Nace D., et al. (2009). Studies on the Salvador I strain of Plasmodium vivax in non-human primates and anopheline mosquitoes. Am. J. Trop. Med. Hyg. 80, 228–235.
Coombs G. L., Fredericks H. J., Cheong W. H., Sandosham A. A., Sta Maria F. L. (1968). The exoerythrocytic schizonts of Plasmodium fieldi. Med. J. Malaya 22, 225–227.
Coton T., Debourdeau P., Schoenlaub P., Grassin F., Maslin J. (2011). [Acute pericarditis associated with Plasmodium ovale malaria]. Med. Trop. (Mars) 71, 79–80.
Dembele L., Gego A., Zeeman A. M., Franetich J. F., Silvie O., Rametti A., et al. (2011). Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One 6, e18162. doi: 10.1371/journal.pone.0018162
Dembele L., Franetich J. F., Lorthiois A., Gego A., Zeeman A. M., Kocken C. H., et al. (2014). Persistence and activation of malaria hypnozoites in long-term primary hepatocyte cultures. Nat. Med. 20, 307–312. doi: 10.1038/nm.3461
Dinko B., Oguike M. C., Larbi J. A., Bousema T., Sutherland C. J. (2013). Persistent detection of Plasmodium falciparum, P. malariae, P. ovale curtisi and P. ovale wallikeri after ACT treatment of asymptomatic Ghanaian school-children. Int. J. Parasitol. Drugs Drug Resist. 3, 45–50. doi: 10.1016/j.ijpddr.2013.01.001
Dissanaike P. (1965). Plasmodium simiovale sp. nov., a new simian malaria parasite from Ceylon. J. Med. Sci. 14, 27–32.
Douglas N. M., Anstey N. M., Buffet P. A., Poespoprodjo J. R., Yeo T. W., White N. J., et al. (2012). The anaemia of Plasmodium vivax malaria. Malar. J. 11, 135. doi: 10.1186/1475-2875-11-135
Duval L., Nerrienet E., Rousset D., Sadeuh Mba S. A., Houze S., Fourment M., et al. (2009). Chimpanzee malaria parasites related to Plasmodium ovale in Africa. PLoS One 4, e5520. doi: 10.1371/journal.pone.0005520
Erel O., Kocyigit A., Avci S., Aktepe N., Bulut V. (1997). Oxidative stress and antioxidative status of plasma and erythrocytes in patients with vivax malaria. Clin. Biochem. 30, 631–639. doi: 10.1016/S0009-9120(97)00119-7
Eyles D. E., Coatney G. R., Getz M. E. (1960). Vivax-type malaria parasite of macaques transmissible to man. Science 131, 1812–1813. doi: 10.1126/science.131.3416.1812
Facer C. A., Rouse D. (1991). Spontaneous splenic rupture due to Plasmodium ovale malaria. Lancet 338, 896. doi: 10.1016/0140-6736(91)91562-9
Ferreira A., Schofield L., Enea V., Schellekens H., Van Der Meide P., Collins W. E., et al. (1986). Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232, 881–884. doi: 10.1126/science.3085218
Flannery E. L., Chatterjee A. K., Winzeler E. A. (2013). Antimalarial drug discovery - approaches and progress towards new medicines. Nat. Rev. Microbiol. 11, 849–862. doi: 10.1038/nrmicro3138
Fonseca L. L., Joyner C. J., Ma H. C., Galinski M. R., Voit E. O. (2017). A model of Plasmodium vivax concealment based on Plasmodium cynomolgi infections in Macaca mulatta. Malar. J. 16, 375. doi: 10.1186/s12936-017-2008-4
Fonseca L. L., Joyner C. J., Saney C. L., Ma H. C., Moreno A., Barnwell J. W., et al. (2018). Analysis of erythrocyte dynamics in Rhesus macaque monkeys during infection with Plasmodium cynomolgi. Malar. J. 17, 410. doi: 10.1186/s12936-018-2560-6
Fremount H. N., Rossan R. N. (1990). Anatomical distribution of developing trophozoites and schizonts of Plasmodium vivax in Aotus lemurinus lemurinus and Saimiri sciureus. J. Parasitol. 76, 428–430. doi: 10.2307/3282681
Fuehrer H. P., Noedl H. (2014). Recent advances in detection of Plasmodium ovale: implications of separation into the two species Plasmodium ovale wallikeri and Plasmodium ovale curtisi. J. Clin. Microbiol. 52, 387–391. doi: 10.1128/JCM.02760-13
Galinski M. R., Barnwell J. W. (2008). Plasmodium vivax: who cares?Malar. J. 7 Suppl 1, S9. doi: 10.1186/1475-2875-7-S1-S9
Galland G. G., Morris C. L., Sullivan, Roberts J. M., Collins W. E. (1998). Changes in Hematologic Values During Infection of New World Monkeys With Plasmodium falciparum and. Contemp. Top. Lab. Anim. Sci. 37, 86–88.
Gallup J. L., Sachs J. D. (2001). The economic burden of malaria. Am. J. Trop. Med. Hyg. 64, 85–96. doi: 10.4269/ajtmh.2001.64.85
Garnham P. C., Bray R. S., Cooper W., Lainson R., Awad F. I., Williamson J. (1955). The pre-erythrocytic stage of Plasmodium ovale. Trans. R Soc. Trop. Med. Hyg. 49, 158–167. doi: 10.1016/0035-9203(55)90042-0
Garnham P. C., Lainson R., Gunders A. E. (1956). Some observations on malaria parasites in a chimpanzee, with particular reference to the persistence of Plasmodium reichenowi and Plasmodium vivax. Ann. Soc. Belg. Med. Trop. (1920) 36, 811–821.
Garnham P. C., Bray R. S., Bruce-Chwatt L. J., Draper C. C., Killick-Kendrick R., Sergiev P. G., et al. (1975). A strain of Plasmodium vivax characterized by prolonged incubation: morphological and biological characteristics. Bull. World Health Organ. 52, 21–32.
Gebreel A. O., Gilles H. M., Prescott J. E. (1985). Studies on the sero-epidemiology of endemic diseases in Libya, IV. Malaria. Ann. Trop. Med. Parasitol. 79, 341–347. doi: 10.1080/00034983.1985.11811930
Goljan J., Felczak-Korzybska I., Nahorski W. L., Myjak P. (2003). Malaria relapse and recrudescence among travellers to the tropics. Int. Marit. Health 54, 92–100.
Graciaa S., Russell R., Chonat S. (2019). Complement Mediated Hemolytic Anemia Secondary to Plasmodium ovale Infection in a Child. J. Pediatr. Hematol. Oncol. 41, 557–558. doi: 10.1097/MPH.0000000000001584
Grigg M. J., Snounou G. (2017). Plasmodium simium: a Brazilian focus ofanthropozoonotic vivax malaria? Lancet Glob. Health 5, e961–e962. doi: 10.1016/S2214-109X(17)30343-1
Groger M., Fischer H. S., Veletzky L., Lalremruata A., Ramharter M. (2017). A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria. Malar. J. 16, 112. doi: 10.1186/s12936-017-1759-2
Guerpillon B., Boibieux A., Perpoint T., Allaouchiche B., Wallon M. (2019). Acute respiratory distress syndrome and Plasmodium ovale malaria. Travel Med. Infect. Dis. 28, 113–114. doi: 10.1016/j.tmaid.2018.06.002
Gunalan K., Sa J. M., Moraes Barros R. R., Anzick S. L., Caleon R. L., Mershon J. P., et al. (2019). Transcriptome profiling of Plasmodium vivax in Saimiri monkeys identifies potential ligands for invasion. Proc. Natl. Acad. Sci. U. S. A. 116, 7053–7061. doi: 10.1073/pnas.1818485116
Gupta D. K., Dembele L., Voorberg-Van Der Wel A., Roma G., Yip A., Chuenchob V., et al. (2019). The Plasmodium liver-specific protein 2 (LISP2) is an early marker of liver stage development. Elife 8, e43362. doi: 10.7554/eLife.43362
Hawking F., Perry W. L., Thurston J. P. (1948). Tissue forms of a malaria parasite, Plasmodium cynomolgi. Lancet 1, 789–789. doi: 10.1016/S0140-6736(48)90857-5
Haydoura S., Mazboudi O., Charafeddine K., Bouakl I., Baban T. A., Taher A. T., et al. (2011). Transfusion-related Plasmodium ovale malaria complicated by acute respiratory distress syndrome (ARDS) in a non-endemic country. Parasitol. Int. 60, 114–116. doi: 10.1016/j.parint.2010.10.005
Held J. R., Contacos P. G., Coatney G. R. (1967). Studies of the exoerythrocytic stages of simian malaria. I. Plasmodium fieldi. J. Parasitol. 53, 225–232. doi: 10.2307/3276565
Hemmer C. J., Holst F. G., Kern P., Chiwakata C. B., Dietrich M., Reisinger E. C. (2006). Stronger host response per parasitized erythrocyte in Plasmodium vivax or ovale than in Plasmodium falciparum malaria. Trop. Med. Int. Health 11, 817–823. doi: 10.1111/j.1365-3156.2006.01635.x
Hoffman S. L., Crutcher J. M., Puri S. K., Ansari A. A., Villinger F., Franke E. D., et al. (1997). Sterile protection of monkeys against malaria after administration of interleukin-12. Nat. Med. 3, 80–83. doi: 10.1038/nm0197-80
Imwong M., Madmanee W., Suwannasin K., Kunasol C., Peto T. J., Tripura R., et al. (2019). Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi. J. Infect. Dis. 219, 695–702. doi: 10.1093/infdis/jiy519
Johnson A. S., Delisca G., Booth G. S. (2013). Warm autoimmune hemolytic anemia secondary to Plasmodium ovale infection: a case report and review of the literature. Transfus. Apher. Sci. 49, 571–573. doi: 10.1016/j.transci.2013.09.006
Joyner C., Barnwell J. W., Galinski M. R. (2015). No more monkeying around: primate malaria model systems are key to understanding Plasmodium vivax liver-stage biology, hypnozoites, and relapses. Front. Microbiol. 6, 145. doi: 10.3389/fmicb.2015.00145
Joyner C., Moreno A., Meyer E. V., Cabrera-Mora M., Ma H. C., Kissinger J. C., et al. (2016). Plasmodium cynomolgi infections in rhesus macaques display clinical and parasitological features pertinent to modelling vivax malaria pathology and relapse infections. Malar. J. 15, 451. doi: 10.1186/s12936-016-1480-6
Joyner C. J., Brito C. F. A., Saney C. L., Joice Cordy R., Smith M. L., Lapp S. A., et al. (2019). Humoral immunity prevents clinical malaria during Plasmodium relapses without eliminating gametocytes. PLoS Pathog. 15, e1007974. doi: 10.1371/journal.ppat.1007974
Kaiser J. (2015). NIH to end all support for chimpanzee research. Science 18. doi: 10.1126/science.aad7458
Kawai S., Annoura T., Araki T., Shiogama Y., Soma S., Takano J. I., et al. (2020). Development of an effective alternative model for in vivo hypnozoite-induced relapse infection: A Japanese macaque (Macaca fuscata) model experimentally infected with Plasmodium cynomolgi. Parasitol. Int. 76, 102096. doi: 10.1016/j.parint.2020.102096
Kitchen S. (1938). The infection of reticulocytes by Plasmodium vivax. Am. J. Trop. Med. Hyg. s1-18, 347–359. doi: 10.4269/ajtmh.1938.s1-18.347
Knobloch J., Mannweiler E., Zum Felde I. (1982). Determination of malarial antibodies by means of screening and differentiating antigens. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 252, 566–571.
Kocken C. H., Remarque E. J., Dubbeld M. A., Wein S., Van Der Wel A., Verburgh R. J., et al. (2009). Statistical model to evaluate in vivo activities of antimalarial drugs in a Plasmodium cynomolgi-macaque model for Plasmodium vivax malaria. Antimicrob. Agents Chemother. 53, 421–427. doi: 10.1128/AAC.00576-08
Koehler J. W., Bolton M., Rollins A., Snook K., Deharo E., Henson E., et al. (2009). Altered immune responses in rhesus macaques co-infected with SIV and Plasmodium cynomolgi: an animal model for coincident AIDS and relapsing malaria. PLoS One 4, e7139. doi: 10.1371/journal.pone.0007139
Kosaisavee V., Suwanarusk R., Chua A. C. Y., Kyle D. E., Malleret B., Zhang R., et al. (2017). Strict tropism for CD71(+)/CD234(+) human reticulocytes limits the zoonotic potential of Plasmodium cynomolgi. Blood 130, 1357–1363. doi: 10.1182/blood-2017-02-764787
Krotoski W. A., Collins W. E., Broderson J. R., Warren M., Krotoski D. M. (1981). The 48-hour exoerythrocytic stage of Plasmodium cynomolgi bastianellii. Am. J. Trop. Med. Hyg. 30, 31–37. doi: 10.4269/ajtmh.1981.30.31
Krotoski W. A., Bray R. S., Garnham P. C., Gwadz R. W., Killick-Kendrick R., Draper C. C., et al. (1982a). Observations on early and late post-sporozoite tissue stages in primate malaria. II. The hypnozoite of Plasmodium cynomolgi bastianellii from 3 to 105 days after infection, and detection of 36- to 40-hour pre-erythrocytic forms. Am. J. Trop. Med. Hyg. 31, 211–225. doi: 10.4269/ajtmh.1982.31.211
Krotoski W. A., Collins W. E., Bray R. S., Garnham P. C., Cogswell F. B., Gwadz R. W., et al. (1982b). Demonstration of hypnozoites insporozoite-transmitted Plasmodium vivax infection. Am. J. Trop. Med. Hyg. 31, 1291–1293. doi: 10.4269/ajtmh.1982.31.1291
Krotoski W. A., Garnham P. C., Bray R. S., Krotoski D. M., Killick-Kendrick R., Draper C. C., et al. (1982c). Observations on early and late post-sporozoite tissue stages in primate malaria. I. Discovery of a new latent form of Plasmodium cynomolgi (the hypnozoite), and failure to detect hepatic forms within the first 24 hours after infection. Am. J. Trop. Med. Hyg. 31, 24–35.
Krotoski W. A., Garnham P. C., Cogswell F. B., Collins W. E., Bray R. S., Gwasz R. W., et al. (1986). Observations on early and late post-sporozoitetissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson andNorth Korean strains of Plasmodium vivax in the chimpanzee. Am. J. Trop. Med. Hyg. 35, 263–274. doi: 10.4269/ajtmh.1986.35.263
Krotoski W. A. (1985). Discovery of the hypnozoite and a new theory of malarial relapse. Trans. R Soc. Trop. Med. Hyg. 79, 1–11.
Lacerda M. V., Fragoso S. C., Alecrim M. G., Alexandre M. A., Magalhaes B. M., Siqueira A. M., et al. (2012). Postmortem characterization of patients withclinical diagnosis of Plasmodium vivax malaria: to what extent does this parasitekill? Clin. Infect. Dis. 55, e67–e74. doi: 10.1093/cid/cis615
Lalremruata A., Magris M., Vivas-Martinez S., Koehler M., Esen M., Kempaiah P., et al. (2015). Natural infection of Plasmodium brasilianum in humans: Man and monkey share quartan malaria parasites in the Venezuelan Amazon. EBioMedicine 2, 1186–1192. doi: 10.1016/j.ebiom.2015.07.033
Lau Y. L., Lee W. C., Tan L. H., Kamarulzaman A., Syed Omar S. F., Fong M. Y., et al. (2013). Acute respiratory distress syndrome and acute renal failure from Plasmodium ovale infection with fatal outcome. Malar. J. 12, 389. doi: 10.1186/1475-2875-12-389
Lee E. Y., Maguire J. H. (1999). Acute pulmonary edema complicating ovale malaria. Clin. Infect. Dis. 29, 697–698. doi: 10.1086/598667
Lim C. S., Tazi L., Ayala F. J. (2005). Plasmodium vivax: recent world expansion and genetic identity to Plasmodium simium. Proc. Natl. Acad. Sci. U. S. A. 102, 15523–15528. doi: 10.1073/pnas.0507413102
Liu G., Li Y., Qin L., Yan Y., Ye Y., Chen Y., et al. (2019). SIV infection aggravates malaria in a Chinese rhesus monkey coinfection model. BMC Infect. Dis. 19, 965. doi: 10.1186/s12879-019-4465-6
Maguire J. D., Baird J. K. (2010). The ‘non-falciparum’ malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies. Ann. Trop. Med. Parasitol. 104, 283–301. doi: 10.1179/136485910X12743554760027
Maheshwari R. K., Czarniecki C. W., Dutta G. P., Puri S. K., Dhawan B. N., Friedman R. M. (1986). Recombinant human gamma interferon inhibits simian malaria. Infect. Immun. 53, 628–630. doi: 10.1128/IAI.53.3.628-630.1986
Maheshwari R. K. (1990). The role of cytokines in malaria infection. Bull. World Health Organ. 68 Suppl, 138–144.
Mapua M. I., Fuehrer H. P., Petrzelkova K. J., Todd A., Noedl H., Qablan M. A., et al. (2018). Plasmodium ovale wallikeri in Western Lowland Gorillas and Humans, Central African Republic. Emerg. Infect. Dis. 24, 1581–1583. doi: 10.3201/eid2408.180010
Martin Polo L., Crespillo-Andujar C., Rey Blas J. R. (2020). Acute myocardial infarction secondary toinfection by Plasmodium ovale. Med. Clin. (Barc) 154, 325–326. doi: 10.1016/j.medcli.2019.03.025
Martinelli A., Culleton R. (2018). Non-human primate malaria parasites: out of the forest and into the laboratory. Parasitology 145, 41–54. doi: 10.1017/S0031182016001335
McHenry A. M., Barnwell J. W., Adams J. H. (2010). Plasmodium vivax DBP binding to Aotus nancymaae erythrocytes is Duffy antigen dependent. J. Parasitol. 96, 225–227. doi: 10.1645/GE-2281.1
Mckenzie F. E., Jeffery G. M., Collins W. E. (2007). Gametocytemia and fever in human malaria infections. J. Parasitol. 93, 627–633. doi: 10.1645/GE-1052R.1
Mehlotra R. K., Blankenship D., Howes R. E., Rakotomanga T. A., Ramiranirina B., Ramboarina S., et al. (2017). Long-term in vitro culture of Plasmodium vivax isolates from Madagascar maintained in Saimiri boliviensis blood. Malar. J. 16, 442. doi: 10.1186/s12936-017-2090-7
Mehrotra A., Dutta G. P. (1994). Role of fatty infiltration during malaria in rhesus monkey. Life Sci. 54, 1861–1868. doi: 10.1016/0024-3205(94)90143-0
Millet P., Anderson P., Collins W. E. (1994a). In vitro cultivation of exoerythrocytic stages of the simian malaria parasites Plasmodium fieldi and Plasmodium simiovale in rhesus monkey hepatocytes. J. Parasitol. 80, 384–388. doi: 10.2307/3283408
Millet P., Nelson C., Galland G. G., Sullivan J. S., Morris C. L., Richardson B. B., et al. (1994b). Plasmodium ovale: observations on the parasite development in Saimiri monkey hepatocytes in vivo and in vitro in contrast with its inability to induce parasitemia. Exp. Parasitol. 78, 394–399. doi: 10.1006/expr.1994.1043
Morgan G. S., Chiodini P., Evans M. (2012). Relapsing malaria: two cases of malaria presenting 8 months after return from Africa despite adherence to antimalarial chemoprophylaxis. Br. J. Gen. Pract. 62, 555–556. doi: 10.3399/bjgp12X657017
Morris C. L., Sullivan J. S., Mcclure H. M., Strobert E., Richardson B. B., Galland G. G., et al. (1996). The Nigerian I/CDC strain of Plasmodium ovale in chimpanzees. J. Parasitol. 82, 444–448. doi: 10.2307/3284083
Mueller I., Zimmerman P. A., Reeder J. C. (2007). Plasmodium malariae and Plasmodium ovale–the “bashful” malaria parasites. Trends Parasitol. 23, 278–283. doi: 10.1016/j.pt.2007.04.009
Mueller I., Galinski M. R., Baird J. K., Carlton J. M., Kochar D. K., Alonso P. L., et al. (2009). Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect. Dis. 9, 555–566. doi: 10.1016/S1473-3099(09)70177-X
Muerhoff A. S., Birkenmeyer L. G., Coffey R., Dille B. J., Barnwell J. W., Collins W. E., et al. (2010). Detection of Plasmodium falciparum, P. vivax, P. ovale, and P. malariae merozoite surface protein 1-p19 antibodies in human malaria patients and experimentally infected nonhuman primates. Clin. Vaccine Immunol. 17, 1631–1638. doi: 10.1128/CVI.00196-10
Nardin E. H., Nussenzweig V., Nussenzweig R. S., Collins W. E., Harinasuta K. T., Tapchaisri P., et al. (1982). Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J. Exp. Med. 156, 20–30. doi: 10.1084/jem.156.1.20
Nardin E. H. (1990). T cell responses in a sporozoite-immunized human volunteer and a chimpanzee. Immunol. Lett. 25, 43–47. doi: 10.1016/0165-2478(90)90089-9
Nichols M. E., Rubinstein P., Barnwell J., Rodriguez De Cordoba S., Rosenfield R. E. (1987). A new human Duffy blood group specificity defined by a murine monoclonal antibody. Immunogenetics and association with susceptibility to Plasmodium vivax. J. Exp. Med. 166, 776–785. doi: 10.1084/jem.166.3.776
Nolder D., Oguike M. C., Maxwell-Scott H., Niyazi H. A., Smith V., Chiodini P. L., et al. (2013). An observational study of malaria in Britishtravellers: Plasmodium ovale wallikeri and Plasmodium ovale curtisi differ significantly in theduration of latency. BMJ Open 3 (5), e002711. doi: 10.1136/bmjopen-2013-002711
Obaldia N. III, Meibalan E., Sa J. M., Ma S., Clark M. A., Mejia P., et al. (2018). Bone Marrow Is a Major Parasite Reservoir inPlasmodium vivax Infection. mBio 9, e00625–18. doi: 10.1128/mBio.00625-18
Obaldia N. III. (2007). Clinico-pathological observations on the pathogenesis of severe thrombocytopenia and anemia induced by Plasmodium vivax infections during antimalarial drug efficacy trials in Aotus monkeys. Am. J. Trop. Med. Hyg. 77, 3–13. doi: 10.4269/ajtmh.2007.77.3
Oguike M. C., Betson M., Burke M., Nolder D., Stothard J. R., Kleinschmidt I., et al. (2011). Plasmodium ovale curtisi and Plasmodium ovale wallikeri circulate simultaneously in African communities. Int. J. Parasitol. 41, 677–683. doi: 10.1016/j.ijpara.2011.01.004
Pasini E. M., Bohme U., Rutledge G. G., Voorberg-Van Der Wel A., Sanders M., Berriman M., et al. (2017). An improved Plasmodium cynomolgi genome assembly reveals an unexpected methyltransferase gene expansion. Wellcome Open Res. 2, 42. doi: 10.12688/wellcomeopenres.11864.1
Peterson M. S., Joyner C. J., Cordy R. J., Salinas J. L., Machiah D., Lapp S. A., et al. (2019). Plasmodium vivax Parasite Load Is Associated With Histopathology in Saimiri boliviensis With Findings Comparable to P vivax Pathogenesis in Humans. Open Forum Infect. Dis. 6, ofz021. doi: 10.1093/ofid/ofz021
Phuong M. S., Lau R., Ralevski F., Boggild A. K. (2016). Parasitological correlates of Plasmodium ovale curtisi and Plasmodium ovale wallikeri infection. Malar. J. 15, 550. doi: 10.1186/s12936-016-1601-2
Ponnudurai T., Lensen A. H., Van Gemert G. J., Bolmer M., Van Belkum A., Van Eerd P., et al. (1990). Large-scale production of Plasmodium vivax sporozoites. Parasitology 101 Pt 3, 317–320. doi: 10.1017/S0031182000060492
Pouvelle B., Gysin J. (1997). Presence of the parasitophorous duct in Plasmodium falciparum and P. vivax parasitized Saimiri monkey red blood cells. Parasitol. Today 13, 357–361. doi: 10.1016/S0169-4758(97)01077-6
Praba-Egge A. D., Montenegro S., Cogswell F. B., Hopper T., James M. A. (2002). Cytokine responses during acute simian Plasmodium cynomolgi and Plasmodium knowlesi infections. Am. J. Trop. Med. Hyg. 67, 586–596. doi: 10.4269/ajtmh.2002.67.586
Prajapati S. K., Singh O. P. (2014). Identification of a vir-orthologous immune evasion gene family from primate malaria parasites. Parasitology 141, 641–645. doi: 10.1017/S003118201300214X
Puri S. K., Maheshwari R. K., Dutta G. P., Friedman R. M., Dhar M. M. (1988). Human interferon-gamma protects rhesus monkeys against sporozoite-induced Plasmodium cynomolgi malaria infection. J. Interferon Res. 8, 201–206. doi: 10.1089/jir.1988.8.201
Puri S. K., Dutta G. P., Levy H. B., Maheshwari R. K. (1996). Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys. J. Interferon Cytokine Res. 16, 49–52. doi: 10.1089/jir.1996.16.49
Richter J., Franken G., Mehlhorn H., Labisch A., Haussinger D. (2010). What is the evidence for the existence ofPlasmodium ovale hypnozoites? Parasitol. Res. 107,1285–1290. doi: 10.1007/s00436-010-2071-z
Rodhain J. (1956). [The pre-erythrocytic forms of Plasmodium vivax in a chimpanzee]. Ann. Soc. Belg. Med. Trop. (1920) 36, 99–103.
Rojo-Marcos G., Cuadros-Gonzalez J., Mesa-Latorre J. M., Culebras-Lopez A. M., De Pablo-Sanchez R. (2008). Acute respiratory distress syndrome in a case of Plasmodium ovale malaria. Am. J. Trop. Med. Hyg. 79, 391–393. doi: 10.4269/ajtmh.2008.79.391
Rossan R. N., Baerg D. C. (1975). Demonstration of exoerythrocytic stages of Plasmodium vivax in Saimiri sciureus. Trans. R Soc. Trop. Med. Hyg. 69, 471–472. doi: 10.1016/0035-9203(75)90100-5
Rutledge G. G., Bohme U., Sanders M., Reid A. J., Cotton J. A., Maiga-Ascofare O., et al. (2017). Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. Nature 542, 101–104. doi: 10.1038/nature21038
Sa J. M., Cannon M. V., Caleon R. L., Wellems T. E., Serre D. (2020). Single-cell transcription analysis of Plasmodium vivax blood-stage parasites identifies stage- and species-specific profiles of expression. PLoS Biol. 18, e3000711. doi: 10.1371/journal.pbio.3000711
Salfelder A., Mannweiler E. (1981). [Immunodiagnostic findings in sera of patients with leishmaniasis, Chagas’ disease, malaria and amebiasis in endemic regions of Venezuela (author’s transl)]. Tropenmed. Parasitol. 32, 194–196.
Saxena Q. B., Biswas S. (1990). Natural killer activity against human K562 tumour cells during Plasmodium cynomolgi malarial infection of rhesus monkeys. FEMS Microbiol. Immunol. 2, 121–124. doi: 10.1016/0928-8244(90)90009-H
Saxena N., Murthy P. S. (2005). Hydrolytic enzyme activity in rhesus monkey placenta during early gestational malaria: histochemical studies. J. Vector Borne Dis. 42, 135–140.
Saxena N., Murthy P. S. (2007). Oxidoreductases in early gestational monkey placenta during maternal malarial infection: histochemical localisation. J. Vector Borne Dis. 44, 116–121.
Saxena N., Pandey V. C., Saxena P. N., Upadhyay S. (1993). Hydrolytic enzymes of rhesus placenta during Plasmodium cynomolgi infection: ultrastructural and biochemical studies. Indian J. Exp. Biol. 31, 54–56.
Schmidt L. H., Squires W. L. (1951). The influence of cortisone on primate malaria. J. Exp. Med. 94, 501–520. doi: 10.1084/jem.94.6.501
Schmidt L. H., Fradkin R., Sesler C., Squires W., Zeyen P. (1987). Attenuation of the virulence of the M strain of Plasmodium cynomolgi during prolonged multiplication in splenectomized rhesus monkeys. Am. J. Trop. Med. Hyg. 37, 460–490. doi: 10.4269/ajtmh.1987.37.460
Schmidt L. H. (1986). Compatibility of relapse patterns of Plasmodium cynomolgi infections in rhesus monkeys with continuous cyclical development and hypnozoite concepts of relapse. Am. J. Trop. Med. Hyg. 35, 1077–1099. doi: 10.4269/ajtmh.1986.35.1077
Sf Kitchen P. P. (1946). Observations on the character of the paroxysm in vivax malaria. J. Natl. Malaria Soc. 5, 57–78.
Shear H. L., Brown J., Gysin J., Jensen J. B., Tharavanij S. (1987). Human and primate malarial sera inhibit Fc receptor-mediated phagocytosis. Am. J. Trop. Med. Hyg. 36, 234–239. doi: 10.4269/ajtmh.1987.36.234
Shortt H. E., Garnham P. C. (1948a). Demonstration of a persisting exo-erythrocytic cycle in Plasmodium cynomolgi and its bearing on the production of relapses. Br. Med. J. 1, 1225–1228. doi: 10.1136/bmj.1.4564.1225
Shortt H. E., Garnham P. C. (1948b). The pre-erythrocytic development of Plasmodium cynomolgi and Plasmodium vivax. Trans. R Soc. Trop. Med. Hyg. 41, 785–795. doi: 10.1016/S0035-9203(48)80006-4
Shortt H. E., Garnham P. C. (1948c). Pre-erythrocytic stage in mammalian malaria parasites. Nature 161, 126. doi: 10.1038/161126a0
Shortt H. E., Garnham P. C., Malamos B. (1948). The pre-erythrocytic stage of mammalian malaria. Br. Med. J. 1, 192–194. doi: 10.1136/bmj.1.4543.192
Shortt H. E., Bray R. S., Cooper W. (1954). Further notes on the tissue stages of Plasmodium cynomolgi. Trans. R Soc. Trop. Med. Hyg. 48, 122–131. doi: 10.1016/0035-9203(54)90004-8
Sinden R. E., Bray R. S., Hartley R., Suhrbier A., Jiang J. B., Krotoski W. A., et al. (1990). An ultrastructural study of the exoerythrocytic schizonts of Plasmodium cynomolgi and P. knowlesi in Macaca mulatta. Acta Trop. 47, 11–21. doi: 10.1016/0001-706X(90)90003-I
Singh P. P., Dutta G. P. (1991). Induction of colony-stimulating factors by Plasmodium cynomolgi components. J. Biol. Regul. Homeost. Agents 5, 59–64.
Sodeman T., Schnitzer B., Durkee T., Jcontacos P. (1970). Fine structure of the exoerythrocytic stage of Plasmodium cynomolgi. Science 170, 340–341. doi: 10.1126/science.170.3955.340
Soulard V., Bosson-Vanga H., Lorthiois A., Roucher C., Franetich J. F., Zanghi G., et al. (2015). Plasmodium falciparum full life cycle and Plasmodium ovale liver stages in humanized mice. Nat. Commun. 6, 7690. doi: 10.1038/ncomms8690
Sullivan J. S., Morris C. L., Mcclure H. M., Strobert E., Richardson B. B., Galland G. G., et al. (1996). Plasmodium vivax infections in chimpanzees for sporozoite challenge studies in monkeys. Am. J. Trop. Med. Hyg. 55, 344–349. doi: 10.4269/ajtmh.1996.55.344
Sullivan J. S., Strobert E., Yang C., Morris C. L., Galland G. G., Richardson B. B., et al. (2001). Adaptation of a strain of Plasmodium vivax from India to New World monkeys, chimpanzees, and anopheline mosquitoes. J. Parasitol. 87, 1398–1403. doi: 10.1645/0022-3395(2001)087[1398:AOASOP]2.0.CO;2
Sullivan J. S., Stewart A., Bounngaseng A., Sullivan J. J., Nace D., Williams A., et al. (2006). Observations on the exoerythrocytic stages of different isolates of Plasmodium cynomolgi in hepatocytes of New World aotus and Saimiri monkeys. J. Parasitol. 92, 202–205. doi: 10.1645/GE-3520RN.1
Sutherland C. J., Tanomsing N., Nolder D., Oguike M., Jennison C., Pukrittayakamee S., et al. (2010). Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J. Infect. Dis. 201, 1544–1550. doi: 10.1086/652240
Sutherland C. J. (2016). Persistent Parasitism: The Adaptive Biology of Malariae and Ovale Malaria. Trends Parasitol. 32, 808–819. doi: 10.1016/j.pt.2016.07.001
Ta T. H., Hisam S., Lanza M., Jiram A. I., Ismail N., Rubio J. M. (2014). First case of a naturally acquired human infection with Plasmodium cynomolgi. Malar. J. 13, 68. doi: 10.1186/1475-2875-13-68
Tang Y., Joyner C. J., Cabrera-Mora M., Saney C. L., Lapp S. A., Nural M. V., et al. (2017). Correction to: Integrative analysis associates monocytes with insufficient erythropoiesis during acute Plasmodium cynomolgi malaria in rhesus macaques. Malar. J. 16, 486. doi: 10.1186/s12936-017-2134-z
Tang Y., Gupta A., Garimalla S., Ma H., Galinski M. R., Styczynski M. P., et al. (2018). Metabolic modeling helps interpret transcriptomic changes during malaria. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 2329–2340. doi: 10.1016/j.bbadis.2017.10.023
Tanner M., Greenwood B., Whitty C. J., Ansah E. K., Price R. N., Dondorp A. M., et al. (2015). Malaria eradication and elimination: views on how to translate a vision into reality. BMC Med. 13, 167. doi: 10.1186/s12916-015-0384-6
Tanwar G. S., Khatri P. C., Sengar G. S., Kochar A., Kochar S. K., Middha S., et al. (2011). Clinical profiles of 13 children with Plasmodium vivax cerebral malaria. Ann. Trop. Paediatr. 31, 351–356. doi: 10.1179/1465328111Y.0000000040
Thomson-Luque R., Adams J. H., Kocken C. H. M., Pasini E. M. (2019). From marginal to essential: the golden thread between nutrient sensing, medium composition and Plasmodium vivax maturation in in vitro culture. Malar. J. 18, 344. doi: 10.1186/s12936-019-2949-x
Tsuboi T., Tachibana M., Kaneko O., Torii M. (2003). Transmission-blocking vaccine of vivax malaria. Parasitol. Int. 52, 1–11. doi: 10.1016/S1383-5769(02)00037-5
van Duivenvoorde L. M., Voorberg-Van Der Wel A., Van Der Werff N. M., Braskamp G., Remarque E. J., Kondova I., et al. (2010). Suppression of Plasmodium cynomolgi in rhesus macaques by coinfection with Babesia microti. Infect. Immun. 78, 1032–1039. doi: 10.1128/IAI.00921-09
Veletzky L., Groger M., Lagler H., Walochnik J., Auer H., Fuehrer H. P., et al. (2018). Molecular evidence for relapse of an imported Plasmodium ovale wallikeri infection. Malar. J. 17, 78. doi: 10.1186/s12936-018-2226-4
Voorberg-van der Wel A., Roma G., Gupta D. K., Schuierer S., Nigsch F., Carbone W., et al. (2017). A comparative transcriptomic analysis ofreplicating and dormant liver stages of the relapsing malaria parasite Plasmodium cynomolgi. Elife 6, e29605. doi: 10.7554/eLife.29605
Voorberg-van der Wel A. M., Zeeman A. M., Nieuwenhuis I. G., Van Der Werff N. M., Klooster E. J., Klop O., et al. (2020). A dual fluorescent Plasmodium cynomolgi reporter line reveals in vitro malaria hypnozoite reactivation. Commun. Biol. 3, 7. doi: 10.1038/s42003-019-0737-3
Warren M., Wharton R. H. (1963). The Vectors of Simian Malaria: Identity, Biology, and Geographical Distribution. J. Parasitol. 49, 892–904. doi: 10.2307/3275715
Warren M., Ali K., Bennett G. F., Sandosham A. A. (1964). Morphology of Plasmodium Fieldi in Different Species of the Genus Macaca. Med. J. Malaya 19, 31.
Welch S. G., Mcgregor I. A., Williams K. (1977). The Duffy blood group and malaria prevalence in Gambian West Africans. Trans. R Soc. Trop. Med. Hyg. 71, 295–296. doi: 10.1016/0035-9203(77)90102-X
Wenk R. E., Stephens I. (2000). Erythrocyte Fy antigen phenotyping helps differentiate so-called benign tertian malarias. Arch. Pathol. Lab. Med. 124, 299–301. doi: 10.1043/0003-9985(2000)124<0299:EFAPHD>2.0.CO;2
Wertheimer S. P., Barnwell J. W. (1989). Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein. Exp. Parasitol. 69, 340–350. doi: 10.1016/0014-4894(89)90083-0
WHO (2016). The global technical strategy for malaria 2016-2030 (Geneva: World Health Organization).
Ylostalo J., Randall A. C., Myers T. A., Metzger M., Krogstad D. J., Cogswell F. B. (2005). Transcriptome profiles of host gene expression in a monkey model of human malaria. J. Infect. Dis. 191, 400–409. doi: 10.1086/426868
Young M. D., Baerg D. C., Rossan R. N. (1975). Parasitological review. Experimental monkey hosts for human plasmodia. Exp. Parasitol. 38, 136–152. doi: 10.1016/0014-4894(75)90046-6
Zeeman A. M., Der Wel A. V., Kocken C. H. (2013). Ex vivo culture of Plasmodium vivax and Plasmodium cynomolgi and in vitro culture of Plasmodium knowlesi blood stages. Methods Mol. Biol. 923, 35–49. doi: 10.1007/978-1-62703-026-7_4
Keywords: relapsing malarias, parasite biology, malaria pathophysiology, parasite-host interactions, Plasmodium vivax, Plasmodium ovale
Citation: Pasini EM and Kocken CHM (2021) Parasite-Host Interaction and Pathophysiology Studies of the Human Relapsing Malarias Plasmodium vivax and Plasmodium ovale Infections in Non-Human Primates. Front. Cell. Infect. Microbiol. 10:614122. doi: 10.3389/fcimb.2020.614122
Received: 05 October 2020; Accepted: 24 December 2020;
Published: 17 February 2021.
Edited by:
Daniel Youssef Bargieri, University of São Paulo, BrazilReviewed by:
Shiroh Iwanaga, Tokyo Medical and Dental University, JapanAmit Sharma, International Centre for Genetic Engineering and Biotechnology, India
Copyright © 2021 Pasini and Kocken. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Clemens H. M. Kocken, kocken@bprc.nl